OTIC
Price:
$0.0085
Market Cap:
$0
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair...[Read more]
Industry
Biotechnology
IPO Date
2014-08-13
Stock Exchange
NASDAQ
Ticker
OTIC
According to Otonomy, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.14. This represents a change of -93.41% compared to the average of -2.15 of the last 4 quarters.
The mean historical PE Ratio of Otonomy, Inc. over the last ten years is -7.17. The current -0.14 PE Ratio has changed 97.66% with respect to the historical average. Over the past ten years (40 quarters), OTIC's PE Ratio was at its highest in in the June 2013 quarter at 0. The PE Ratio was at its lowest in in the March 2013 quarter at -19.76.
Average
-7.17
Median
-5.18
Minimum
-26.00
Maximum
-1.15
Discovering the peaks and valleys of Otonomy, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 134.82%
Maximum Annual PE Ratio = -1.15
Minimum Annual Increase = -61.30%
Minimum Annual PE Ratio = -26.00
Year | PE Ratio | Change |
---|---|---|
2021 | -2.62 | -56.67% |
2020 | -6.05 | 123.83% |
2019 | -2.70 | 134.82% |
2018 | -1.15 | -39.18% |
2017 | -1.89 | -56.06% |
2016 | -4.31 | -60.03% |
2015 | -10.78 | 76.56% |
2014 | -6.10 | -39.32% |
2013 | -10.06 | -61.30% |
The current PE Ratio of Otonomy, Inc. (OTIC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.79
5-year avg
-2.88
10-year avg
-7.17
Otonomy, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Otonomy, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Otonomy, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Otonomy, Inc.'s PE Ratio?
How is the PE Ratio calculated for Otonomy, Inc. (OTIC)?
What is the highest PE Ratio for Otonomy, Inc. (OTIC)?
What is the 3-year average PE Ratio for Otonomy, Inc. (OTIC)?
What is the 5-year average PE Ratio for Otonomy, Inc. (OTIC)?
How does the current PE Ratio for Otonomy, Inc. (OTIC) compare to its historical average?